您好,欢迎您

2024 ESMO|肺癌相关专场口头摘要信息速览!

07月17日
整理:肿瘤资讯
来源:2024 ESMO 官网

2024欧洲肿瘤学会(ESMO 2024)年会即将来袭,此次会议将于欧洲中部夏令时间(CET)9月13日-17日在西班牙巴塞罗那举行。
近日,ESMO官方已公布除Late-breaking abstracts(LBA)外的所有口头摘要题目及作者信息。【肿瘤资讯】特别整理本次公布的肺癌相关专场重磅研究(主要包含MO:mini oral;O:oral)标题,以飨读者。

Proffered paper session: NSCLC metastatic

本专场有5个LBA摘要待确认(TBC)
专场时间:2024年9月14日,08:30-10:00
专场地点:Barcelona Auditorium - Hall 2


摘要号:1253O

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors

NVL-655治疗ALK阳性(ALK+)实体瘤的I/II期ALKOVE-1研究

讲者:Alexander E. Drilon (New York, United States of America, NY)


Proffered paper session: Non-metastatic NSCLC

本专场有4个LBA摘要待确认(TBC)
专场时间:2024年9月15日,10:15-11:45
专场地点:Barcelona Auditorium - Hall 2


Mini oral session 1: Non-metastatic NSCLC

本专场有3个LBA摘要待确认(TBC)
专场时间:2024年9月15日,10:15-11:45
专场地点:Barcelona Auditorium - Hall 2


摘要号:1786MO

BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase 2 study

BMS-986012(抗岩藻糖基单唾液酸神经节苷脂-1 [fuc-GM 1])联合卡铂+依托泊苷+纳武利尤单抗(CE/NIVO)作为广泛期小细胞肺癌(ES-SCLC)的一线(1L)治疗:一项随机化II期研究的中期分析(IA)

讲者:Ewa Kalinka (Łódź, Poland)


摘要号:1910MO

ARTIMES: Automated Response evaluation to Treatment In MESothelioma

ARTIMES研究:间皮瘤治疗的自动反应评估

讲者:Kevin B. Groot Lipman (Amsterdam, Netherlands)


摘要号:1240MO

Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with Stage III unresectable NSCLC

定量放射组学检测III期不可切除的非小细胞肺癌患者放化疗后症状性肺炎

讲者:Jarushka Naidoo (Dublin, Ireland, MD)


Mini oral session 2: Non-metastatic NSCLC

本专场有3个LBA摘要待确认(TBC)
专场时间:2024年9月16日,14:45-16:15
专场地点:Sevilla Auditorium - Hall 2


摘要号:1241MO

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the Phase 3 LAURA study

不可切除的III期EGFR突变NSCLC在根治性放化疗(CRT)后接受奥希替尼治疗的疗效:III期LAURA研究的中枢神经系统(CNS)和远处进展分析

讲者:Shun Lu (Shanghai, China);陆舜 上海交通大学医学院附属胸科医院


摘要号:1206MO

ALINA: exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

ALINA研究:术后接受辅助阿来替尼 vs化疗的ALK+非小细胞肺癌(NSCLC)患者的探索性生物标志物分析

讲者:Ben J. Solomon (Melbourne, Australia, VIC)


摘要号:1207MO

Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase 2 POTENTIAL study

新辅助纳武利尤单抗单药治疗高危临床I期非小细胞肺癌:一项II期POTENTIAL研究

讲者:Yasuhiro Tsutani (Osaka, Japan, Hiroshima)


摘要号:1242MO

The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: a randomized controlled, open-label phase II study

在根治性放疗基础上加用丙酸倍氯米松吸入剂治疗局部晚期NSCLC患者 :一项随机对照、开放标签II期研究

讲者:JIE ZHANG (Shanghai, China);张洁 上海市肺科医院


摘要号:1208MO

Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study

围手术期吡非尼酮治疗肺癌伴特发性肺纤维化(IPF)的III期试验:NEJ034研究

讲者:Yukinobu Goto (Tsukuba, Japan)


摘要号:1243MO

A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914

一项比较每周一次卡铂联合白蛋白结合型紫杉醇与每日一次低剂量卡铂用于老年不可切除局部晚期NSCLC患者(≥75岁)同步放化疗的III期研究:JCOG1914

讲者:Shota Omori (Yufu, Japan)


Mini oral session: NSCLC metastatic

本专场有5个LBA摘要待确认(TBC)
专场时间:2024年9月14日,10:15-11:45
专场地点:Santander Auditorium - Hall 5


摘要号:1254MO

Safety and Antitumor Activity of Zipalertinib in NSCLC Patients (pts) with EGFR Exon 20 Insertion (ex20ins) Mutations Who Received Prior Amivantamab

Zipalertinib在既往接受过埃万妥单抗治疗的携带EGFR 20号外显子插入(ex20ins)突变的NSCLC患者中的安全性和抗肿瘤活性

讲者:Antonio Passaro (Milan, Italy)


摘要号:1255MO

A Phase II Safety and Efficacy Study of PM8002/BNT-327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

PM8002/BNT-327联合化疗治疗EGFR突变NSCLC的疗效和安全性

讲者:Yi-Long Wu (Guangzhou, China, Guangdong);吴一龙 广东省人民医院


摘要号:1256MO

Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors

Zidesamtinib(NVL-520)治疗ROS 1融合阳性实体瘤的I/II期ARROS-1研究

讲者:Benjamin Besse (Villejuif, Cedex, France, CEDEX)


摘要号:1257MO

ABBV-400, a c-Met Protein–Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) With Advanced EGFR Wildtype (WT) Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC): Results From a Phase 1 Study

ABBV-400,一种c-Met蛋白靶向抗体-药物偶联物(ADC),用于晚期EGFR野生型(WT)非鳞状(NSQ)非小细胞肺癌(NSCLC)患者(Pts):一项I期研究的结果

讲者:María De Miguel (Madrid, Spain)


摘要号:1258MO

Low dose versus standard dose pembrolizumab for treatment of stage 4 stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial

低剂量与标准剂量帕博利珠单抗治疗4期非小细胞肺癌:NVALT-30临床试验预先计划的中期分析结果

讲者:Michel Van den Heuvel (Nijmegen, Netherlands)


摘要号:1259MO

Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced Non-Small Cell Lung Cancer (NSCLC): an open-label, multicenter phase 2 trial (IFCT-1904 ENCO-BRAF)

Encorafenib联合binimetinib治疗既往未经治疗的BRAF V600 E突变型晚期非小细胞肺癌(NSCLC)患者:一项开放标签、多中心II期试验(IFCT-1904 ENCO-BRAF)

讲者:David Planchard (Villejuif, Cedex, France)


如有遗漏,欢迎留言补充!


责任编辑:肿瘤资讯-云初
排版编辑:肿瘤资讯-云初


评论
07月18日
马利平
河南省肿瘤医院 | 放疗科
欧洲肺癌大会也会公布很多新的临床研究